Inyx ROE

Mitä Inyx tekee? Inyx Inc, listed under the ticker IYXI with ISIN US4618681013, is a pharmaceutical company headquartered in New York City, United States. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. Inyx Inc has 572 employees and completed its initial public offering on February 19, 2003. The company focuses on developing and acquiring niche pharmaceutical products and drug delivery systems for therapeutic areas such as respiratory and dermatological applications. Its operations include the development of prescription and over-the-counter pharmaceutical products, as well as specialty consulting services. Inyx Inc utilizes niche drug delivery capabilities to develop its own products, with product categories encompassing Metered Dose Inhalers (MDIs) using CFC and HFA propellants, Dry Powder Inhalers (DPIs), Metered Dose Pump Sprays for nasal and oral use, Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions and Injectables, Solid Dose formulations, and various services including Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support, and Integrated Project Management. The company's activities are centered around creating innovative solutions in drug delivery and pharmaceutical development within specific therapeutic areas. Inyx on yksi Eurpooliin suosituimmista yhtiöistä.